Orchid Pharma Limited
₹833.05-₹58.90 (-6.6%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹3,739 Cr
- P/E
- 51.8x
- Revenue
- ₹922 Cr
Price chart
Technical chartScreen technicals →+17.5% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -16.3%
- 3M
- -16.6%
- 6M
- +32.5%
- 1Y
- +17.5%
- 5Y
- +104.0%
52-week range
Day change -₹58.90 (-6.6%) from ₹892 to ₹833 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ORCHPHARMA, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Revenue grew 12.6% YoY
Concerns1
- Negative free cash flow (₹10 Cr)
Rule-based from financial data. Not advice.
About the company
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India.
Read moreShow less
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
- Sector
- Healthcare
- Shares outstanding
- 5.1 Cr shares
- ISIN
- INE191A01027
- BSE code
- 524372
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹3,739 Cr
- P/E
- 51.8x
- P/B
- 2.8x
- Earnings yield
- 1.9%
- 52-week high
- ₹1,107.20
- 52-week low
- ₹478.35
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹922 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 12.6%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 11.6%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹131 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 907.7%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹18.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 26.9%
Solvency and efficiency
- Current ratio
- 4.58
- Debt / Equity
- 0.11
- Debt / Assets
- 0.09
- Financial leverage
- 1.27
- Cash / Market cap
- 22.5%
- Cash per share
- ₹166.19
- Debtor days
- 84 days
- Inventory turnover
- 1.83
- Cash conversion cycle
- 148 days
Where the revenue went
Some FY2025 lines are not reported, so the ones that are appear as a table.
| Line | FY2025 |
|---|---|
| Sales | ₹922 Cr |
| Expenses | ₹798 Cr |
| Operating profit | ₹124 Cr |
| Other income | ₹32 Cr |
| Interest | ₹15 Cr |
| Depreciation | ₹34 Cr |
| Profit before tax | ₹106 Cr |
| Tax and other | ₹0 Cr |
| Net profit | ₹106 Cr |
Revenue and net profit
Revenue grew 12.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹451 Cr | -₹117 Cr |
| FY2022 | ₹557 Cr | -₹5 Cr |
| FY2023 | ₹666 Cr | ₹54 Cr |
| FY2024 | ₹819 Cr | ₹95 Cr |
| FY2025 | ₹922 Cr | ₹106 Cr |
Cash flows
FY2025: ₹27.0 Cr from operations, -₹10.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹24 Cr | ₹91 Cr |
| FY2022 | ₹90 Cr | ₹203 Cr |
| FY2023 | ₹13 Cr | -₹14 Cr |
| FY2024 | ₹131 Cr | -₹185 Cr |
| FY2025 | ₹27 Cr | -₹10 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹922 Cr+12.6%1Y
- Net profit
- ₹106 Cr+11.6%1Y
- Cash from operations
- ₹27 Cr
- Free cash flow
- -₹10 Cr
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹922 Cr | ₹124 Cr | — | ₹106 Cr | ₹27 Cr | -₹10 Cr | — | +12.6% | +11.6% |
Monthly returns
Month-by-month returns of ORCHPHARMA across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹1,697 Cr |
| Equity capital | ₹51 Cr |
| Reserves | ₹1,273 Cr |
| Borrowings | ₹175 Cr |
| Other liabilities | ₹198 Cr |
| Assets | ₹1,697 Cr |
| Fixed assets | ₹613 Cr |
| Capital work in progress | ₹44 Cr |
| Investments | ₹69 Cr |
| Other assets | ₹970 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ORCHPHARMA trades at 51.8x earnings against a peer median of 52.6x.
Not shown (no positive earnings and no EV / Sales): Dishman Carbogen Amcis Limited, Suven Life Sciences Ltd.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Orchid Pharma LimitedORCHPHARMAthis company | ₹3,739 Cr | 51.8x | 2.8x | — | — |
| Dishman Carbogen Amcis LimitedDCAL | ₹4,132 Cr | — | 1.0x | -1.9% | 67.5x |
| Artemis Medicare Services LimitedARTEMISMED | ₹4,059 Cr | 42.6x | 4.0x | 10.8% | 32.0x |
| Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,008 Cr | 83.0x | 15.1x | 29.4% | 48.1x |
| INNOVA CAPTAB LIMITEDINNOVACAP | ₹3,945 Cr | 51.8x | 4.6x | 9.4% | 34.2x |
| RPG Life Sciences LimitedRPGLIFE | ₹3,806 Cr | 34.2x | 6.9x | 23.5% | 27.7x |
| SENORES PHARMACEUTICALS LIMITEDSENORES | ₹3,750 Cr | 307.0x | 5.2x | 0.6% | 545.5x |
| Indraprastha Medical Corporation LtINDRAMEDCO | ₹3,742 Cr | 21.4x | 5.7x | 25.9% | 17.5x |
| Suven Life Sciences Ltd.SUVEN | ₹3,490 Cr | — | 3.3x | -0.9% | -1728.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
ORCHPHARMA since 1 January, against earlier years.
Historical volatility
ORCHPHARMA's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 13.0% |
| FY2022 | 11.0% |
| FY2023 | 13.0% |
| FY2024 | 14.0% |
| FY2025 | 13.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹922 Cr |
| Costs | |
| Interest | ₹15 Cr |
| Expenses | ₹798 Cr |
| Operating profitOperating Profit | ₹124 Cr |
| Other income and charges | |
| Profit before tax | ₹106 Cr |
| Tax | |
| Net profitNet Profit | ₹106 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹1,697 Cr |
| Equity capitalEquity Capital | ₹51 Cr |
| Reserves | ₹1,273 Cr |
| Borrowings | ₹175 Cr |
| Other liabilitiesOther Liabilities | ₹198 Cr |
| AssetsTotal Assets | ₹1,697 Cr |
| Fixed assetsFixed Assets | ₹613 Cr |
| Capital work in progressCWIP | ₹44 Cr |
| Investments | ₹69 Cr |
| Other assetsOther Assets | ₹970 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹27 Cr |
| Investing cash flowCash from Investing Activity | -₹37 Cr |
| Financing cash flowCash from Financing Activity | ₹25 Cr |
| Change in cashNet Cash Flow | ₹16 Cr |
Learn while you research
Academy chapters picked for Orchid Pharma Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 51.8, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read